Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative Colitis
Abivax SA (Euronext PARIS:FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural
Abivax finished a required check-in meeting with the FDA about their new medicine for a serious gut disease. This is a positive step forward, but the medicine still needs official approval before patients can use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.